Table 1 Comparison of basal steroid measurements of the MS patients with fingolimod treatment and healthy subjects
Parameter | Patients (n = 19) median (range) | Healthy controls (n = 15) median (range) | P value |
|---|---|---|---|
Age (yrs) | 34.2 (21.3–44.6) | 31.5 (27–46) | 0.63 |
Basal plasma cortisol (ng/ml) (N: 50–250 ng/ml) | 151 (77–237) | 164 (113–300) | 0.11 |
Basal plasma aldosterone (N: < 0.24 ng/ml) | 0.064 (0.023–0.20) | 0.1 (0.04–0.21) | 0.38 |
Basal plasma DHEA (ng/ml) (M: 0.61–16.3 ng/ml F: 1.02–11.85 ng/ml) | 6 (2.2–11.8) | 7 (2.6–14.2) | 0.15 |
Basal plasma DHEA-S (ng/ml) (M: 480–3340 ng/ml F: 440–3220 ng/ml) | 1083 (779–2825) | 1427 (572–3110) | 0.22 |
Basal plasma 11-deoxycortisol (ng/ml) (M: 0.14–1.2 ng/ml F: 0.17–1.2 ng/ml) | 0.32 (0.07–1.28) | 0.25 (0.07–0.54) | 0.058 |
Basal plasma 11-deoxycorticosterone (ng/ml) (M: ≤0.15 ng/ml F: ≤0.18 ng/ml) | 0.02 (0.001–0.29) | 0.05 (0.01–0.11) | 0.74 |
Basal plasma 17OH- pregnenolone (ng/ml) (M: < 1.28 ng/ml F: < 9.09 ng/ml) | 1.3 (0.14–7.6) | 0.52 (0.16–3.84) | 0.28 |
Basal plasma 17OH- progesterone (M: < 2.20 ng/ml F: < 2.85 ng/ml) | 0.98 (0.20–1.94) | 1.25 (0.18–2.59) | 0.09 |
Basal plasma progesterone (M: < 0.20 ng/ml F: 2.7–31 ng/ml) | 0.07 (0.006–13.85) | 0.08 (0.01–21.8) | 0.27 |
Basal plasma pregnenolone (N: ≤ 3.25 ng/ml) | 0.52 (0.16–2.25) | 0.77 (0.42–1.12) | 0.79 |
Basal plasma 21- deoxycortisol (N: < 0.5 ng/ml) | 0.06 (0.02–0.12) | 0.08 (0.03–0.31) | 0.89 |
Basal plasma androstenedione (N: 0.20–2.50 ng/ml) | 0.79 (0.32–1.50) | 1.06 (0.23–2.2) | 0.26 |